Анемия при воспалительных заболеваниях кишечника у детей
https://doi.org/10.15690/vsp.v15i2.1530
Аннотация
Анемия — одно из наиболее частых осложнений воспалительных заболеваний кишечника, встречающихся, по разным данным, у 6–74% пациентов с такими формами патологии. Патогенез и лечение анемии при воспалительных заболеваниях кишечника имеют ряд особенностей. Так, например, не всякая анемия — железодефицитная и, соответственно, ее коррекция не ограничивается применением только препаратов железа. В обзоре проанализирована многофакторная природа анемии при воспалительных заболеваниях кишечника, ее влияние на течение и прогноз основного заболевания, описаны современные терапевтические средства.
Об авторах
А. О. АнушенкоРоссия
врач-педиатр, гастроэнтеролог, сотрудник гастроэнтерологического отделения с гепатологической группой НЦЗД, ассистент кафедры факультетской педиатрии № 1 педиатрического факультета РНИМУ им. Н.И. Пирогова Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-15-82
А. С. Потапов
Россия
Е. Г. Цимбалова
Россия
О. Б. Гордеева
Россия
Список литературы
1. Fernandes A, Bacalhau S, Cabral J. Pediatric inflammatory bowel disease: is it still increasing? Acta Med Port. 2011; 24 Suppl 2:333–338.
2. Benchimol E, Guttmann A, Griffiths A, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58(11): 1490–1497. doi: 10.1136/gut.2009.188383.
3. Hammer T, Nielsen KR, Burisch J, et al. DOP010. Incidence of inflam matory bowel diseases in the Faroe Islands from 1960–2014: A 54-year overview from a population-based cohort. J Crohns Colitis. 2015;9 (suppl 1):S24. doi:10.1093/ecco-jcc/jju027.038.
4. Nielsen KR, Hammer T, Burisch J, et al. Su1070 Incidence of inflammatory bowel diseases in the Faroe Islands from 1960–2014: A 54-year overview from a population-based cohort. Gastroenterology. 2015;148(4):S399. doi: 10.1016/S0016- 5085(15)31342-1.
5. Ravikumara M, Sandhu B. Epidemiology of inflammatory bowel diseases in childhood. Indian J Pediatr. 2006;73(8):717–721. doi: 10.1007/bf02898451.
6. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–951. doi: 10.3109/00365521.2015.1014407.
7. Jose F, Garnett E, Vittinghoff E, et al. Development of Extraintestinal Manifestations in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2009;15(1):63–68. doi: 10.1002/ibd.20604.
8. Mamula P, Markowitz J, Baldassano R. Pediatric Inflammatory Bowel Disease. New York, Springer; 2008. Vol. 8. p. 88.
9. Диагностика и лечение железодефицитной анемии у детей / Под ред. А.Г. Румянцева, Н.А. Коровиной. — М.; 2004. 48 с. [Diagnostika i lechenie zhelezodefitsitnoi anemii u detei. Ed by Rumyantsev A.G., Korovina N.A. Moscow; 2004. 48 p. (In Russ).]
10. Тарасова И.С. Разработка и научное обоснование скрининга железодефицитных состояний у подростков: Автореф. дис. … докт. мед. наук. — М.; 2013. 67 с. [Tarasova IS. Razrabotka i nauchnoe obosnovanie skrininga zhelezodefitsitnykh sostoyanii u podrostkov. [dissertation abstract] Moscow; 2013. 67 p. (In Russ).]
11. World Health Organization. Anaemia [Internet]. Geneva, Switzerland: WHO; 2011 [cited 2016 Apr 19]. Available from: http://www.who.int/topics/anaemia/en/.
12. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6(2):142–150. doi: 10.1002/ibd.3780060214.
13. Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2001;7(3): 250–255. doi: 10.1097/00054725-200108000-00011.
14. Gomollon F, Gisbert J. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009;15(37):4659–4665. doi: 10.3748/wjg.15.4659.
15. Долгов В.В., Луговская С.А., Почтарь М.Е., Федорова М.М. Лабораторная диагностика нарушений обмена железа. — СПб.: Витал Диагностикс; 2002. 52 с. [Dolgov VV, Lugovskaya SA, Pochtar’ ME, Fedorova MM. Laboratornaya diagnostika narushenii obmena zheleza. St. Petersburg: Vital Diagnostiks; 2002. 52 p. (In Russ).]
16. Kugathasan S, Judd R, Hoffmann R, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state wide populationbased study. J Pediatr. 2003;143(4):525–531. doi: 10.1067/s0022-3476(03)00444-x.
17. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clinical Chem. 2002;48(7):1066–1076.
18. Cartwright GE, Lauritsen MA, Jones PJ, et al. The anemia of infection. I. Hypoferremia, hypercupremia, and alterations in porphyrin metabolism in patients. J Clin Invest. 1946;25(1):65–80. doi: 10.1172/JCI101690.
19. Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010;95(2): 175–178. doi: 10.3324/haematol.2009.017046.
20. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica. 2010;95(2):199–205. doi: 10.3324/haematol.2009.009985.
21. Weiss G, Goodnough L. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi: 10.1056/nejmra041809.
22. Grimm MС. Inflammatory bowel disease: genes, germs and the gastrointestinal immune system. Today’s Life Science. 2001;13(1):24–30.
23. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(7Suppl.1):44–49. doi: 10.1016/j.amjmed.2003.12.011.
24. Ruiz-Arguelles G. Altitude above sea level as a variable for definition of anemia. Blood. 2006;108(6):2131–2132. doi: 10.1182/blood-2006-04-016352.
25. Voegtlin M, Vavricka S, Schoepfer A, et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross sectional study in patients from private practices and university hospitals. J Crohns Colitis. 2010;4(6):642–648. doi: 10.1016/ j.crohns.2010.07.008.
26. Goodhand J, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3): 513–519. doi: 10.1002/ibd.21740.
27. naspghan.org [Internet]. Monitoring disease activity in pediatric IBD patients. A case-based monograph focusing on pediatric IBD [updated 2009 Dec 15; cited 2016 Mar 12]. Available from: http://www.naspghan.org/files/documents/pdfs/cme/podcasts/MonitoringDiseaseActivity_PediatricIBDPatients.pdf.
28. Beard J. One person’s view of iron deficiency, development, and cognitive function. Am J Clin Nutr. 1995;62(4):709–710.
29. Kretchmer N, Beard JL, Carlson S. The role of nutrition in the development of normal cognition. Am J Clin Nutr. 1996; 63(6):997–1001.
30. Lozoff B, Beard J, Connor J, et al. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev. 2006; 64(5):34–43. doi: 10.1301/nr.2006.may.s34-s43.
31. Bridges K, Pearson H. Anemias and other red cell disorders. USA: McGraw-Hill; 2008. 97 p.
32. Skikne B, Punnonen K, Caldron P, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86(11): 923–927. doi: 10.1002/ajh.22108.
33. Dignass A, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211–222. doi: 10.1093/ecco-jcc/jju009.
34. Wallach J. Interpretation of diagnostic test. New York; 2008. 1200 р.
35. Brailsford S, Lunec J, Winyard P, et al. A possible role for ferritin during inflammation. Free Radic Res Commun. 1985;1(2): 101–109. doi: 10.3109/10715768509056542.
36. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13(12): 1545–1553. doi: 10.1002/ibd.20285.
37. Cronin C, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol. 2001;96(8): 2296–2298. doi: 10.1111/j.1572-0241.2001.04032.x.
38. Headstrom P, Rulyak S, Lee S. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn’s disease. Inflamm Bowel Dis. 2008;14(2):217–223. doi: 10.1002/ibd.20282.
39. Alkhouri R, Hashmi H, Baker R, et al. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56(1):89–92. doi: 10.1097/MPG.0b013e 31826a105d.
40. Goldberg N. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2013; 6: 61-70. doi: 10.2147/CEG.S43493.
41. Suominen P, Punnonen K, Rajamaki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood. 1998; 92(8):2934-2939.
42. Ботвиньева В.В., Гордеева О.Б., Потапов А.С., и др. Оценка показателей воспалительного ответа и состояния периферического гемопоэза при неспецифическом язвенном колите у детей // Педиатрическая фармакология. — 2013. — Т. 10. — №5. — С. 52–55. [Botvin'eva VV, Gordeeva OB, Potapov AS, et al. Assessment of inflammatory response indicators and peripheral hemopoiesis at non-specific ulcerative colitis in children. Pediatricheskaya farmakologiya. 2013;10(5):52–55. (In Russ).] doi: 10.15690/pf.v10i5.823.
43. Баркова Э.Н. Патофизиологическое обоснование хронодиагностики и хронотерапии дефицита железа / Сб. научных статей: Патогенез и фармакокоррекция экстремальных и терминальных состояний. — М.; 1995. С. 11–14. [Barkova EN. Patofiziologicheskoe obosnovanie khronodiagnostiki i khronoterapii defitsita zheleza. In: Patogenez i farmakokorrektsiya ekstremal’nykh i terminal’nykh sostoyanii. Moscow; 1995. p. 11–14. (In Russ).]
44. Stein J, Dignass A. Management of iron deficiency anemia in inflammatory bowel disease — a practical approach. Ann Gastroenterol. 2013;26(2):104–113.
45. Baynes R. Assessment of iron status. Clin Biochem. 1996; 29(3):209–215. doi: 10.1016/0009-9120(96)00010-k.
46. Thorstensen K, Romslo I. The transferrin receptor: Its diagnostic value and its potential as therapeutic target. Scand J Clin Lab Invest. 1993;53(suppl215):113–120. doi: 10.3109/00365519309090703.
47. Baillie F, Morrison A, Fergus I. Soluble transferrin receptor: A discriminating assay for iron deficiency. Clin Lab Haematol. 2003;25(6):353–357. doi: 10.1046/j.0141-9854.2003.00548.x.
48. Flowers CH, Skikne BS, Covell AM, Cook JD. The clinical measurement of serum transferrin receptor. J Lab Clin Med. 1989;114(4):368–377.
49. Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med. 2013; 22(4):585–591.
50. Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;6(3): 62–72. doi: 10.4291/wjgp.v6.i3.62.
51. Sanad M, Gharib A. Urinary hepcidin level as an early predictor of iron deficiency in children: A case control study. Ital J Pediatr. 2011;37:37. doi: 10.1186/1824-7288-37-37.
52. Konz T, Montes-Bayon M, Vaulont S. Hepcidin quantification: methods and utility in diagnosis. Metallomics. 2014;6(9): 1583–1590. doi: 10.1039/c4mt00063c.
53. Arnold J, Sangwaiya A, Manglam V, et al. Presence of hepcidin-25 in biological fluids: Bile, ascitic and pleural fluids. World J Gastroenterol. 2010;16(17):2129–2133. doi: 10.3748/wjg.v16.i17.2129.
54. Arnold J, Sangwaiya A, Bhatkal B, et al. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol. 2009;21(4):425–429. doi: 10.1097/MEG.0b013e32830e2885.
55. Pakoz Z, Cekic C, Arabul M, et al. Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015;810942. doi: 10.1155/2015/810942.
56. Nagy J, Lakner L, Poor VS, et al. Serum prohepcidin levels in chronic inflammatory bowel diseases. J Crohns Colitis. 2010; 4(6):649–653. doi: 10.1016/j.crohns.2010.07.010.
57. Павлов А.Д. Биологическая и клиническая роль эритропоэтина и его рецептора в негемопоэтических тканях // Вопросы гематологии, онкологии и иммунопатологии в педиатрии. — 2004. — Т.3. — №1. — С. 12–20. [Pavlov AD. Biological and clinical role of erythropoietin and its receptor in non-hematopoietic tissues. Voprosy gematologii, onkologii i immunopatologii v pediatrii. 2004;3(1):12–20. (In Russ).]
58. Павлов А.Д., Морщакова Е.Ф. Синдром неадекватной продукции эритропоэтина на анемию // Гематология и трансфузиология. — 1999. — Т. 44. — №3. — С. 30–32. [Pavlov AD, Morshchakova EF. Sindrom neadekvatnoi produktsii eritropoetina na anemiyu. Gematol Transfuziol. 1999;44(3):30–32. (In Russ).]
59. Katsanos KH, Tatsioni A, Natsi D, et al. Recombinant human erythropoietin in patients with inflammatory bowel disease and refractory anemia: a 15-year single center experience. J Crohns Colitis. 2012;6(1):56–61. doi: 10.1016/j.crohns.2011.07.004.
60. Basseri R, Nemeth E, Vassilaki M, et al. Hepcidin is a key mediator of anemia of inflammation in Crohn’s disease. J Crohns Colitis. 2013;7(8):286–291. doi: 10.1016/j.crohns.2012.10.013.
61. Wine E, Mack D, Hyams J, et al. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis. 2013;7(11):916–922. doi: 10.1016/j.crohns.2012.12.012.
62. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004;126(4):989–996. doi: 10.1053/j.gastro.2004.01.012.
63. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol. 2010;16(22):2720–2725. doi: 10.3748/wjg.v16. i22.2720.
64. Moreno Chulilla JA, Romero Colas MS, Gutierrez Martin M. Classification of anemia for gastroenterologists. World J Gastroenterol. 2009;15(37):4627–4637. doi: 10.3748/wjg.15.4627.
65. Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001;60(6):2406–2411. doi: 10.1046/j.1523-1755. 2001.00077.x.
66. d’Onofrio G, Chirillo R, Zini G, et al. Simultaneous measurement of reticulocyte and red blood cell indexes in healthy subjects and patients with microcytic and macrocytic anemia. Blood. 1995;85(3):818–823.
67. Piva E, Brugnara C, Spolaore F, Plebani M. Clinical utility of reticulocyte parameters. Clin Lab Med. 2015;35(1):133–163. doi: 10.1016/j.cll.2014.10.004.
68. Rodak B. Hematology: clinical principles and applications. 3 ed. Philadelphia: Saunders; 2007. 220 р.
69. Black M. Micronutrient deficiencies and cognitive functioning. J Nutr. 2003;133(11 Suppl 2):3927–3931.
70. de Andraca Oyarzun I, Salas Aliaga I, de la Parra Cieciwa A, Gonzalez Lopez B. Mother–child interaction and child behavior in preschool children with a history of iron-deficiency anemia in infancy. Arch Latinoam Nutr. 1993;43(3):191–198.
71. Olson C, Acosta L, Hochberg N, et al. Anemia of inflammation is related to cognitive impairment among children in Leyte, the Philippines. PLoS Neglect Trop D. 2009;3(10):533. doi: 10.1371/ journal.pntd.0000533.
72. Gonzalez H, Malpeli A, Etchegoyen G. Acquisition of visuomotor abilities and intellectual quotient in children aged 4–10 years: relationship with micronutrient nutritional status. Biol Trace Elem Res. 2007;120(1-3):92–101. doi: 10.1007/s12011-007-8023-5.
73. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18(8):555–559. doi: 10.1089/jir.1998.18.555.
74. Nemeth E, Tuttle M, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093. doi: 10.1126/science.1104742.
75. Gisbert J, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1299–1307. doi: 10.1111/j.1572-0241.2008.01846.x.
76. Cable R, Carlson B, Chambers L, et al. Practice guidelines for blood transfusion: a compilation from recent peer reviewed literature [Internet]. New York; 2002 [cited 2016 Jan 27]. Available from: http://chapters.redcross.org/br/indianaoh/hospitals/transfusionguidelines.htm.re.
77. Davies P, Robertson S, Hedge S, et al. Calculating the required transfusion volume in children. Transfusion. 2007;47(2):212–216. doi: 10.1111/j.1537-2995.2007.01091.x.
78. Elzik M, Dirschl D, Dahners L. Correlation of transfusion volume to change in hematocrit. Am J Hematol. 2006;81(2):145–146. doi: 10.1002/ajh.20517.
79. Joint Working Party of the Transfusion and Clinical Haematology Task Forces of the British Committee for Standards in Haematology. Guidelines for the clinical use of red cell transfusions. Br J Haematol. 2001;113(1):24–31. doi: 10.1046/j.1365-2257.1998.00151.x.
80. Crosby E, Ferguson D, Hume H, et al. Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J. 1997;156 Suppl 11:1–24.
81. Национальный стандарт РФ. Кровь донорская и ее компоненты. Руководство по применению компонентов донорской крови. — М.; 2010. [Natsional’nyi standart RF. Krov’ donorskaya i ee komponenty. Rukovodstvo po primeneniyu komponentov donorskoi krovi. Moscow; 2010. (In Russ).]
82. Румянцев А.Г., Аграненко В.А. Гемотрансфузионная терапия в педиатрии и неонатологии. — М.: Макс Пресс; 2002. 643 с. [Rumyantsev AG, Agranenko VA. Gemotransfuzionnaya terapiya v pediatrii i neonatologii. Moscow: Maks Press; 2002. 643 p. (In Russ).]
83. Oldenburg B, Koningsberger J, Van Berge Henegouwen G, et al. Iron and inflammatory bowel disease. Aliment Pharmacol Ther. 2001;15(4):429–438. doi: 10.1046/j.1365- 2036.2001.00930.x.
84. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190–1197. doi: 10.1136/gut.2003.035758.
85. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008;6(3–4):93–102. doi: 10.3121/cmr.2008.811.
86. de Silva A, Mylonaki M, Rampton D. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis. 2003;9(5):316–320. doi: 10.1097/00054725-200309000-00005.
87. Авдеев В.Г., Моисеев С.В. Анемия при болезни Крона // Клиническая фармакология и терапия. — 2013. — Т. 22. — №1. — С. 1–6. [Avdeev VG, Moiseev SV. Anemiya pri bolezni Krona. Klinicheskaya farmakologiya i terapiya. 2013;22(1):1–6. (In Russ).]
88. Toblli J, Cao G, Olivieri L, et al. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant. 2010;25(11):3631–3140. doi: 10.1093/ndt/gfq260.
89. Милованов Ю.С., Милованова Л.Ю., Добросмыслов И.А. Железа (III) гидроксид сахарозный комплекс (Венофер) или его копии в лечении анемии у больных хронической болезнью почек: на что ориентироваться при выборе препарата? // Клиническая нефрология. — 2012.— №1. — С. 49–59. [Milovanov YuS, Milovanova LYu, Dobrosmyslov IA. Iron sucrose in treatment of anemia in chronic kidney disease — original and generic drugs: what are the guidelines in drug choose? Klinicheskaya nefrologiya. 2012;(1):49–59. (In Russ).]
90. Beshara S, Sorensen J, Lubberink M. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003;120(5):853–859. doi: 10.1046/j.1365- 2141.2003.03590.x.
91. Moore R, Gaskell H, Rose H, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders. 2011;11:4. doi: 10.1186/1471-2326-11-4.
92. Kulnigg S, Stoinov S, Simanenkov V. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial. Am J Gastroenterol. 2007;103(5):1182–1192. doi: 10.1111/j.1572-0241.2007.01744.x.
93. Hachemi S, Mutalib M, Chadokufa S, et al. Assessment of safety and efficacy of ferric carboxymaltose (Ferinject®) in the management of iron deficiency with anaemia (IDA) or without anaemia in children and adolescents with inflammatory bowel disease (IBD). Abstracts of the 10th Congress of ECCO — European Crohn’s and Colitis Organisation. New York; 2015. p. 266.
94. Laass MW, Straub S, Chainey S, et al. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol. 2014;14:184. doi: 10.1186/1471- 230x-14-184.
95. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol. 2003;14(4):511–519. doi: 10.1093/annonc/mdg167.
96. Littlewood T, Bajetta E, Nortier J, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo controlled trial. J Clin Oncol. 2001; 19(11):2865–2874.
97. Kaltwasser J, Kessler U, Gottschalk R, et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol. 2001; 28(11):2430–2436.
98. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003; 24(9):1021–1029. doi: 10.1093/carcin/bgg126.
99. Arcasoy M, Amin K, Karayal A, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 2002;82(7):911–918. doi: 10.1097/01.lab.00000 20415.72863.40.
100. Румянцев А.Г., Морщакова Е.Ф., Павлов А.Д. Эритропоэтин: диагностика, профилактика и лечение анемий. — М.; 2003. 448 с. [Rumyantsev AG, Morshchakova EF, Pavlov AD. Eritropoetin: diagnostika, profilaktika i lechenie anemii. Moscow; 2003. 448 p. (In Russ).]
101. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113(21): 5277–5286. doi: 10.1182/blood-2008-12-195651.
Рецензия
Для цитирования:
Анушенко А.О., Потапов А.С., Цимбалова Е.Г., Гордеева О.Б. Анемия при воспалительных заболеваниях кишечника у детей. Вопросы современной педиатрии. 2016;15(2):128-140. https://doi.org/10.15690/vsp.v15i2.1530
For citation:
Anushenko A.O., Potapov A.S., Tsimbalova Ye.G., Gordeeva O.B. Anemia in Inflammatory Bowel Diseases in Children. Current Pediatrics. 2016;15(2):128-140. (In Russ.) https://doi.org/10.15690/vsp.v15i2.1530